• PCR231 The Socio-Economic Burden on Caregivers of Pediatric Autistic Population in Europe: A Systematic Review

    Dec 1, 2023, 00:00

  • HTA29 Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessments of Orphan Drugs Due to Exceeding the Sales Threshold in Germany

    Dec 1, 2023, 00:00

  • EE722 Cost-Utility Analysis for Haemate-P in the Treatment of Von Willebrand Disease

    Dec 1, 2023, 00:00

  • RWD152 Describing the Management of Spondyloarthropathies in French Primary Care: An EHR Study Exploring Regional Differences

    Dec 1, 2023, 00:00

  • EE285 Economic Evaluation of Knee Arthroscopic Surgery: A Comparison of Ambulatory and In-Patient Knee Arthroscopic Surgery in Thailand

    Dec 1, 2023, 00:00

  • EE262 Indirect Cost Burden for Individuals Living with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Europe

    Dec 1, 2023, 00:00

  • EPH98 Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study

    Dec 1, 2023, 00:00

  • CO115 The Interpretation and Grading of Evidence Derived From Interim Analyses for the Assessment of the Pharmacotherapeutic Efficacy of Medicines

    Dec 1, 2023, 00:00

  • MSR58 It's Alive! Feasibility and Benefits of Living Cost-Effectiveness Modeling Following a Living SLR

    Dec 1, 2023, 00:00

  • HPR168 Assessment of Equity in Healthcare Financing for Uganda

    Dec 1, 2023, 00:00

  • EE209 Can the German Efficiency Frontier Approach Support Decision-Making Processes for Pricing New Medicines? An Application to Second-Line Interventions of Transplant-Ineligible Diffuse Large B-Cell Lymphoma

    Dec 1, 2023, 00:00

  • HPR68 Comprehensive Genomic Profiling Approaches in Europe and the US: A Review of Guidelines and Recommendations for Solid Tumors

    Dec 1, 2023, 00:00

  • CO30 Disease Burden and Efficacy of Current Treatment for Non-Neuronopathic MPS II Patients: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • PCR178 Illness-Related Uncertainty in Relapsing-Remitting Multiple Sclerosis: Psychometric Properties of the MUIS Questionnaire

    Dec 1, 2023, 00:00

  • RWD137 Real-World Osteoporosis Drug Utilization in Patients with Recurrent Osteoporotic Fracture: A Nationwide Cohort Study in South Korea

    Dec 1, 2023, 00:00

  • RWD45 Describing Medication Switching Patterns Among Adults With Rheumatoid Arthritis From 2016-2022 Using Real-World Data

    Dec 1, 2023, 00:00

  • EE235 Economic Evaluations of Medical Devices Used in the Treatment of Breast Cancer: A Systematic Review

    Dec 1, 2023, 00:00

  • PT15 Comparing the Impact of Random Forest Vs Bayesian G-Computation on Matching-Adjusted Indirect Comparisons of Treatments Between Trials: A Simulation Study

    Dec 1, 2023, 00:00

  • RWD55 Retrospective Observational Study of Real-World Treatment Patterns and Financial Burden in Patients With Premenopausal Metastatic HR+/HER2- Breast Cancer

    Dec 1, 2023, 00:00

  • RWD12 Wayfind-R: A Global, Real-World Precision Oncology Registry – Socioeconomic Features

    Dec 1, 2023, 00:00

  • EE54 Costs of Proton Radiotherapy and Photon Radiotherapy for Non-Small Cell Lung Cancer in the Netherlands Using a Time-Driven Activity-Based Costing Approach

    Dec 1, 2023, 00:00

  • SA18 Public Health Economic Modelling in Evaluations of Salt and Alcohol Policies: A Scoping Review

    Dec 1, 2023, 00:00

  • MT5 Mapping Facilities, Equipment and Trained Personnel of Radiotherapy in Greece

    Dec 1, 2023, 00:00

  • HTA6 The Value of Looking Beyond Overall Survival: The Role of Oncology-Relevant Endpoints in HTA / Payer Decision-Making

    Dec 1, 2023, 00:00

  • PCR91 Patients’ Needs in Assessing Long COVID: A Review of Relevant Concepts and Patient-Reported Outcomes

    Dec 1, 2023, 00:00

  • PCR33 The Application of Stated Preference Methods in Rare Disease: A Systematic Review

    Dec 1, 2023, 00:00

  • MSR114 Reducing Mortality From Malignant Neoplasms: The Promising Role of Modern Antineoplastic Drugs in Lung Cancer Treatment

    Dec 1, 2023, 00:00

  • EE183 Cost-Effectiveness of Raltegravir Oral Granules Prophylaxis in Neonates to Prevent HIV Mother-to-Child Transmission in Brazil

    Dec 1, 2023, 00:00

  • HTA326 Indication-Based Pricing of the Pharmaceuticals in Croatia: Case-Study Modelling Excercise

    Dec 1, 2023, 00:00

  • HTA93 Time to Reimbursement of Novel Anticancer Drugs in Ireland Compared to Six European Countries and the UK

    Dec 1, 2023, 00:00

  • SA61 Economic Burden of Patients in the United States with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Focused Literature Review

    Dec 1, 2023, 00:00

  • EPH138 Descriptive Analysis of Communication About Cancer Prevention and Screening on the Social Network Twitter

    Dec 1, 2023, 00:00

  • The Role of Artificial Intelligen From Economic Modelling to Clinical Decision Making

    Dec 1, 2023, 00:00

  • EE592 Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Filipino Adults Aged ≥50 Years

    Dec 1, 2023, 00:00

  • PCR143 European Quality of Life Five Dimension (EQ-5D) Utility Values for Clinical Health States in Fabry Disease (FD): Insights from Pegunigalsidase Alpha Clinical Trials

    Dec 1, 2023, 00:00

  • HSD100 Opportunities and Barriers to Hub-and-Spoke Delivery Models for Advanced Therapy Medicinal Products in Europe: A Scoping Review

    Dec 1, 2023, 00:00

  • HSD9 Access to Precision Medicine in Mexico: Differences of Therapy Patterns for ALK+ and EGFR+ Non-Small Cell Lung Cancer (NSCLC) Patients

    Dec 1, 2023, 00:00

  • EE746 Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England

    Dec 1, 2023, 00:00

  • MSR21 Methodological Aspects of a COVID-19 Vaccine Discrete Choice Experiment Survey in Canada, Germany, UK, and US General Populations

    Dec 1, 2023, 00:00

  • EE467 Cost-Effectiveness and Budget Impact Analyses Using Real World Data from Brazilian Health Care Insurance Companies in the Treatment of Iron Deficiency in Patients with Heart Failure

    Dec 1, 2023, 00:00

  • Differences and New Developments in HTA Around the World

    Dec 1, 2023, 00:00

  • CO48 A Systematic Review of Effectiveness and Safety of Acupuncture on Suicidal Behavior

    Dec 1, 2023, 00:00

  • EE446 Cost-Effectiveness Analysis of Nuvaxovid Vaccination for Japanese Elderly Population

    Dec 1, 2023, 00:00

  • HTA63 Qualitative Analysis of Value-Based Contract Experience, Perception, and Future Adoption across Geographies

    Dec 1, 2023, 00:00

  • EE136 The Socio-Economic Value of Adult Immunization: Results from a Comprehensive Literature Review of Four Immunization Programs in Ten Countries

    Dec 1, 2023, 00:00

  • CO114 Comparative 30-Day Postoperative Outcomes between Robotic-Assisted Low Anterior Resection (RALAR) and Laparoscopic Low Anterior Resection (LLAR) Among Rectal Cancer Patients in Japan

    Dec 1, 2023, 00:00

  • EPH181 Are Social Networks Harming Our Teens? Assessing the Plausibility of a Link between Social Network Use and Depression Using a Microsimulation Model

    Dec 1, 2023, 00:00

  • SA7 Emerging Biomarkers in Metastatic Castration Resistant Prostate Cancer As Evaluated in Early Phase Clinical Trials: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • EE338 Economic Impact of Herpes Zoster and Postherpetic Neuralgia on Healthcare Resource Use in Sweden

    Dec 1, 2023, 00:00

  • HPR8 Drug Approvals for Advanced Breast Cancer in Brazil: Historical Perspective and Comparative Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • HTA328 An Updated Analysis of the Early Access Reform and Trends Observed in the Evaluation by the HAS

    Dec 1, 2023, 00:00

  • HPR89 Payer Rejections and Prescription Abandonment Among Patients Newly Prescribed Oral Anticoagulants for Venous Thromboembolism

    Dec 1, 2023, 00:00

  • PCR141 The Impact of Duchenne Muscular Dystrophy on Caregiver Employment: A Survey in Europe, Japan, and the United States

    Dec 1, 2023, 00:00

  • HPR191 Incentives for Using Biosimilars in France and Europe: Analysis, Assessment and Perspectives

    Dec 1, 2023, 00:00

  • RWD144 Coded Diagnoses Versus Proxy-Based Diagnoses in Primary Care: Registration By General Practitioners in the PHARMO GP Data

    Dec 1, 2023, 00:00

  • EPH70 Claims Data Analysis of Health Care Resource Use and Costs of Respiratory Syncytial Virus Prevention in Infants in Germany

    Dec 1, 2023, 00:00

  • EE740 Costs and Clinical Outcomes of Colorectal Cancer Surgeries: Results From the Emilia-Romagna Surgical Colorectal Audit (ESCA)

    Dec 1, 2023, 00:00

  • HTA123 The View from the Sandbox: Implementing a Safe Space to Co-Develop and Test Innovations in HTA

    Dec 1, 2023, 00:00

  • EE535 Assessing the Impact of Adverse Events on Cost-Effectiveness Results for NICE Single Technology Appraisals of Oncology Medicines

    Dec 1, 2023, 00:00

  • HTA173 Time to Access Orphan Medicines in Greece

    Dec 1, 2023, 00:00

  • EE417 Budget Impact of Efmoroctocog Alfa in Treatment of Severe Haemophilia a Patients in Turkey

    Dec 1, 2023, 00:00

  • EE483 A Cost-Impact Analysis of a Novel Diagnostic Test to Assess Community-Acquired Pneumonia Etiology in the Emergency Departments: A French Perspective

    Dec 1, 2023, 00:00

  • HSD27 A 2013-2019 Comparative Study of Patient Safety Culture at 16 Hospitals in Shimane, Japan

    Dec 1, 2023, 00:00

  • EPH222 Temporal Analysis of Diabetes, Hypertension, and Asthma Prevalen A Comparative Study in European Countries (FRANCE, SPAIN, BELGIUM, ROMANIA, AND ITALY) Using a Real-World Ambulatory Medical Database (2018-2022)

    Dec 1, 2023, 00:00

  • PCR221 Real-World Adherence to Anti-PCSK9 Monoclonal Antibody (mAb) and Its Impact on Economic Burden of Cardiovascular Diseases in Patients with Hypercholesterolemia: A Retrospective Cohort Study in China

    Dec 1, 2023, 00:00

  • HTA192 What Must Change if Future Evidence Pricing and Access Challenges Are to Be Successfully Overcome?

    Dec 1, 2023, 00:00

  • HTA126 How Did French Health Technology Assessment Body (Transparency Committee, TC, of the HAS) Assess Drugs with Clinical Development Based on Single Arm Trials in the Last Three Years?

    Dec 1, 2023, 00:00

  • EE441 Estimating Changes in Lifetime Tax Revenue and Transfer Payments Associated with the Pediatric Immunization Program in Belgium

    Dec 1, 2023, 00:00

  • EPH235 The Road to an HIV Cure: Approaches and Strategies in Current Clinical Trials

    Dec 1, 2023, 00:00

  • HTA133 The Number of NICE Appraisal Terminations Is Increasing, and Products With Multiple Indications Are Disproportionally Impacted

    Dec 1, 2023, 00:00

  • EE220 Cost-Effectiveness Analysis of Netupitant/Palonosetron for Chemotherapy Induced Nausea and Vomiting in Brazilian Private Healthcare System Perspective

    Dec 1, 2023, 00:00

  • MSR17 Can Machine Learning Accurately Predict Payer Behavior?

    Dec 1, 2023, 00:00

  • EE410 Retrospective Database Analysis of Healthcare Resource Utilization and Costs in Patients With Vitiligo in Quebec, Canada

    Dec 1, 2023, 00:00

  • MT62 Virtual Reality Training on Medical Devices: A Proof of Concept Study

    Dec 1, 2023, 00:00

  • HTA34 Demonstrating Similar or Greater Health Benefits Based on Indirect Eviden A Review of NICE Evaluations That Include a Cost-Comparison Approach

    Dec 1, 2023, 00:00

  • SA20 The Effectiveness and Safety of Intra-Articular Injection Using Collagen in Knee Osteoarthritis: Systematic Review

    Dec 1, 2023, 00:00

  • RWD16 Identifying Oncology Effectiveness Endpoints Using Administrative Secondary Databases: An Example Utilising Hospital Episode Statistics in England

    Dec 1, 2023, 00:00

  • EE186 A Comparative Cost Analysis between Dalbavancin, Oritavancin and Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Spain

    Dec 1, 2023, 00:00

  • EE478 Obesity-Related Outcomes and Cost Impact of Weight Loss in Saudi Arabian Privately Insured Adults

    Dec 1, 2023, 00:00

  • PCR101 Patient-Centric-Approach and Personalized Clinical Trials to Increase Patients Participation in Drug Development: Insight from a Targeted Literature Review (TLR)

    Dec 1, 2023, 00:00

  • EPH15 Transmission Dynamics and Vaccination Strategies for Chikungunya Virus (CHIKV): An Outbreak Simulation Study in Rome, Italy

    Dec 1, 2023, 00:00

  • EPH157 Developing an Analysis to Determine the Value of Time When Delaying the Who's Seasonal Influenza Vaccine Strain Selection Recommendation

    Dec 1, 2023, 00:00

  • EE670 Management Costs of Grade 3/4 Adverse Events Associated with Emerging and Existing Systemic Therapies for Metastatic Colorectal Cancer with at Least Two Prior Lines of Therapy in Italy, Portugal, Spain, and the United States

    Dec 1, 2023, 00:00

  • MSR128 Developing a Checklist to Increase Efficiency of VBA Code

    Dec 1, 2023, 00:00

  • HTA10 Exploring the Impact of End-of-Life Designation on Access to Oncology Therapies in the United Kingdom

    Dec 1, 2023, 00:00

  • HTA31 Health Technology Assessment (HTA) of Clinical Care Pathways: Peritoneal Dialysis Versus Hemodialysis

    Dec 1, 2023, 00:00

  • CO103 Modelled Impact of Nirsevimab for All Infants in Preventing Respiratory Syncytial Virus (RSV): Related Hospitalizations and Costs in the Brazilian Private Healthcare System

    Dec 1, 2023, 00:00

  • EE425 Estimating HCP Labor Time and Cost Saving with the Use of Rapid Rituximab Infusions Versus Standard Rituximab Infusions for the Treatment of Adults with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma in Induction Phase

    Dec 1, 2023, 00:00

  • MT58 Implications of VivaSight-DL: Procedural Impact of a Camera-Integrated Double Lumen Tube

    Dec 1, 2023, 00:00

  • PCR44 Work and Activity Impairment in Individuals With Chronic Kidney Disease According to Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Use

    Dec 1, 2023, 00:00

  • Innovations in Modeling for Health Technology Assessment

    Dec 1, 2023, 00:00

  • MT77 Assessing the Environmental Impact Associated With Disruptive Surgical Bleeding

    Dec 1, 2023, 00:00

  • EPH188 Social Determinants of Health and Treatment Receipt Among Privately and Publicly Insured Adults Diagnosed With Cancer in the United States

    Dec 1, 2023, 00:00

  • RWD92 Evaluation of Second and Third Generation Tyrosine Kinase Inhibitor As First-Line Therapy for Non–Small-Cell Lung Cancer Patients: A Multi-Institutional Study in Taiwan

    Dec 1, 2023, 00:00

  • EPH189 Factors Associated with Biosimilar Prescription for Anti-Cancer Biologics Among 58,915 Patients in Europe

    Dec 1, 2023, 00:00

  • HTA325 Valuing Life - Decision-Making for Medicines in Australia: A Retrospective Analysis (2020-2022)

    Dec 1, 2023, 00:00

  • MSR9 Adjusting for Switches to Multiple Treatments in Randomised Controlled Trials: A Comparison of Inverse Probability Weighting and Two-Stage Estimation Methods

    Dec 1, 2023, 00:00

  • EE395 Economic Burden and Cost Drivers of Dystrophic Epidermolysis Bullosa: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE495 Cost of Spinal Muscular Atrophy(SMA) Management in Turkiye

    Dec 1, 2023, 00:00

  • EE727 The Budgetary Impact of Introducing Expanded Haemodialysis, Enabled by Theranova (HDX), Compared to High-Flux Haemodialysis (HF-HD) in Private Sector in the Kingdom of Saudi Arabia

    Dec 1, 2023, 00:00

  • HPR14 Applications for Tafamidis (Vyndaqel®) Under a Managed Access Protcol in Ireland

    Dec 1, 2023, 00:00

  • MSR121 Use of External Control Arms in Pharmaceutical Submissions to the National Institute for Health and Care Excellence for Technology Appraisals: A Targeted Review

    Dec 1, 2023, 00:00

  • RWD81 Annual Nationwide Epidemiological and Health Insurance Burden of Hip Osteoarthritis in Hungary: A Burden of Disease Study Based on Real World Data

    Dec 1, 2023, 00:00

  • HTA146 Early Access in Fran Reasons for Refusals and Impact on Market Access

    Dec 1, 2023, 00:00

  • HTA252 Shorter Time to Market for Pharmaceuticals Assessed in the Nordic HTA-Collaboration FINOSE

    Dec 1, 2023, 00:00

  • EE253 Comparative Efficacy of Beclomethasone/Formoterol/Glycopyrronium (BDP/FOR/GLY) Vs Budesonide/Glycopyrrolate/Formoterol (BUD/GLY/FOR): Indirect Comparison in Chinese Patients with Chronic Obstructive Pulmonary Disease

    Dec 1, 2023, 00:00

  • EPH253 Epidemiology Disease Burden of Polycistic Ovary Syndrome Based on Routinely Collected Health Insurence Claims Data Between 2010-2019

    Dec 1, 2023, 00:00

  • Novel Approaches to Patient Communication, Data Collection, and Involvement in Research

    Dec 1, 2023, 00:00

  • HSD93 Towards Diagnosing Rare Diseases: Referral Behavior of Physicians in Europe

    Dec 1, 2023, 00:00

  • PCR194 A Global Perspective on Self-Reported Productivity Losses Associated With Osteogenesis Imperfecta

    Dec 1, 2023, 00:00

  • EE378 Real-World Data Establishing HCRU and Costs for the Treatment of Patients With Intermediate- to High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Utilizing Medicare Claims Data

    Dec 1, 2023, 00:00

  • EE369 Cost-Effectiveness Analysis of Pembrolizumab as a Second-Line Therapy for Advanced Urothelial Carcinoma in the United States

    Dec 1, 2023, 00:00

  • EE399 Exploring the Economic Consequences of Caring for Patients With Rare Diseases: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • RWD126 Assessment of Cutaneous Malignant Melanoma Knowledge, Tanning Attitude, and Sun-Protective Behavior in Gree A Significant Gap in the National Preventive Health Strategy

    Dec 1, 2023, 00:00

  • HTA270 Integrating Environmental Sustainability into HTA: The State of the Art and Possible Trajectories

    Dec 1, 2023, 00:00

  • HTA165 Unmet Medical Need in Norwegian Clinical Practice and Cost-Effectiveness Analysis of Polatuzumab in Combination With R-CHP Compared to R-CHOP in Patients With Previously Untreated DLBCL With an IPI Score of Three and Above

    Dec 1, 2023, 00:00

  • EPH211 The Public Health Impact of mRNA-1273 Fall Booster Vaccination in the Netherlands

    Dec 1, 2023, 00:00

  • EE166 Healthcare Resource Use and Economic Burden of Stroke Among People with Type 2 Diabetes: A Real-World Evidence Study in France

    Dec 1, 2023, 00:00

  • RWD136 Use and Potential of Real-World Data (RWD) and Real-World Evidence (RWE) to Inform Pre-Market Regulatory Decisions: A Scoping Review

    Dec 1, 2023, 00:00

  • PCR152 Exploring Which Proxy Conditions Are Conceptually Similar to Alopecia Areata, in Terms of Patients Lived Experience and Health-Related Quality of Life: A Scoping Review to Inform HTA Submission

    Dec 1, 2023, 00:00

  • HTA45 Study of HTA Timelines and Outcomes for MHRA-Approved NASs in the Post-Brexit UK via Reliance/Work-Sharing Routes

    Dec 1, 2023, 00:00

  • EPH4 Burden of Disease and Cost of Permanent Productivity Loss of Cardiovascular Disease (CVD) in South America (SA)

    Dec 1, 2023, 00:00

  • HSD62 The Emotional and Information Seeking Experience of Locally Advanced Cervical Cancer: Qualitative Research Findings from Brazil

    Dec 1, 2023, 00:00

  • HSD6 The CONNACT Program for Knee Osteoarthritis Can Potentially Lower 2-Year Costs of Outpatient Treatment

    Dec 1, 2023, 00:00

  • EE663 The Disease and Economic Burden of Hepatocellular Carcinoma in Australia

    Dec 1, 2023, 00:00

  • EPH89 Epidemiological Disease Burden of Female Infertility, N.O.S, Based on Routinely Collected Health Insurance Claims Data Between 2010-2019

    Dec 1, 2023, 00:00

  • PCR189 Health-Related Quality of Life and Its Drivers for Patients Living With Glioblastoma in Europe: A Systematic Review

    Dec 1, 2023, 00:00

  • HTA324 Recent Landscape of Drug Re-Assessments by G-BA – What Is the Impact of New Evidence on the Benefit Assessment Outcome?

    Dec 1, 2023, 00:00

  • EE260 Cost-Effectiveness Analysis of Daratumumab Triplet Therapy Vs Carfilzomib Duplet Therapy in Patients with Relapsed or Refractory Multiple Myeloma in Egypt from Payer Perspective

    Dec 1, 2023, 00:00

  • RWD96 Burden of Chronic Obstructive Pulmonary Disease (COPD) Patients Uncontrolled Despite Triple-Therapy in France

    Dec 1, 2023, 00:00

  • EE200 Cost of Illness of Spinal Muscular Atrophy in Turkey

    Dec 1, 2023, 00:00

  • RWD89 Economic Burden of Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring KRASG12C Mutation in Spain

    Dec 1, 2023, 00:00

  • HPR170 Time to Reimbursement in Ireland; Utilizing Regression Analysis to Assess Factors Contributing to Overall Timelines

    Dec 1, 2023, 00:00

  • PCR127 Needs and Experiences of Patients and Healthcare Professionals Towards Shared Decision Making in Multiple Myeloma Clinical Practi A Qualitative Study in Europe

    Dec 1, 2023, 00:00

  • EE343 Cost-Utility and Cost-Effectiveness of Rapid Recovery After Joint Replacement: The Payer's Perspective

    Dec 1, 2023, 00:00

  • HSD120 Tafamidis in the Treatment of Transthyretin Amyloid Cardiomyopathy in Poland: Epidemiological Data and Demographic Data from an Expanded Access Program

    Dec 1, 2023, 00:00

  • HPR51 Better Safe Than Sorry? Identification of Drug Combinations for Targeted Price Regulation in German Claims Data

    Dec 1, 2023, 00:00

  • PCR65 Assessment of the EQ-5D and DMD-QoL for Duchenne Muscular Dystrophy: A Patient and Caregiver Study

    Dec 1, 2023, 00:00

  • MSR100 Exploring Methods to Include Carbon Footprint into an HTA: The Case of Remote Patient Management

    Dec 1, 2023, 00:00

  • HPR49 Clinical Rationales Support Access to Novel Combination Therapies in Oncology: Are We Trying to Play a New Game with the Old Rules?

    Dec 1, 2023, 00:00

  • PCR40 Unmet Medical Needs and Treatment Preferences for Systemic Treatments in Patients with Moderate to Severe Psoriasis: A Cross-Sectional Survey Study in China

    Dec 1, 2023, 00:00

  • EE265 Cost-Effectiveness of Efmoroctocog Alfa in Treatment of Severe Hemophilia A Patients in Turkey

    Dec 1, 2023, 00:00

  • OP17 Mapping Pharma Market Access Executives in Greece

    Dec 1, 2023, 00:00

  • EPH223 Clinical, Economic, and Humanistic Burden of Atherosclerotic Cardiovascular Disease (ASCVD) and Familial Hypercholesterolemia (FH) in Latin America: A Scoping Review (SR)

    Dec 1, 2023, 00:00

  • EE552 Healthcare Resource Utilization in Alpha-Mannosidosis: Results from an International Caregiver Survey

    Dec 1, 2023, 00:00

  • PCR98 Reduced Dialysis Adherence and Greater Medication Use Associated with Increased Itch Severity

    Dec 1, 2023, 00:00

  • EE488 Budget Impact Analysis of Oral Treatment With Nirmaltrevir+Ritonavir for COVID-19 in Argentina

    Dec 1, 2023, 00:00

  • HSD128 Preferences of Healthcare Providers in Switzerland for Attributes of Pediatric Hexavalent Vaccines

    Dec 1, 2023, 00:00

  • HTA254 Potential Discrepancies/Misalignments in Future EU-HTA Appraisals the POLIVY and Stelara JA3 PICO Example

    Dec 1, 2023, 00:00

  • EE712 Budget Impact Analysis of Faricimab for Treating Patients With Diabetes Macular Edema or Neovascular Age-Related Macular Degeneration in El Salvador, Honduras, and Dominican Republic

    Dec 1, 2023, 00:00

  • Has the Centers for Medicare Medicaid Services Implicitly Adopted a Value Framework for Medicare Drug Price Negotiations? [Editor's Choice]

    Dec 1, 2023, 00:00

  • HTA319 3-Year Report Card: RWE Collection in Germany

    Dec 1, 2023, 00:00

  • HPR111 ATMPs in Europe: Do We Have an Access Gap?

    Dec 1, 2023, 00:00

  • MSR140 Current Trends in Survival Extrapolation Methods: A Review of NICE Health Technology Appraisals for Oncology Drugs

    Dec 1, 2023, 00:00

  • RWD4 Socioeconomic Burden of Obesity – Increased Rate and Duration of Sick Leave in Patients Living with Obesity: A Cross-Sectional Claims Data Analysis in Germany

    Dec 1, 2023, 00:00

  • CO67 Development of an Investigator Global Assessment of Severity in Propionic Acidemia

    Dec 1, 2023, 00:00

  • EE392 The Potential Impact of Delandistrogene Moxeparvovec on Work Productivity on Individuals With Duchenne Muscular Dystrophy in the United States (US)

    Dec 1, 2023, 00:00

  • EPH272 It Is Known Since 1922 at 2B Level of Evidence, Yet Not Used: Attitude Towards Intraosseous Medication

    Dec 1, 2023, 00:00

  • PCR96 Long Term Consequences of COVID-19 in Quality of Life in Patients Discharged From Hospital: Systematic Review

    Dec 1, 2023, 00:00

  • HTA111 Population, Intervention, Comparator, Outcomes (PICO) of ATMPs and Potential Impact on the Upcoming EU Regulation on HTA

    Dec 1, 2023, 00:00

  • EE598 Cost-Utility of Influenza Vaccination for the Brazilian Elderly Population With a High Dose Quadrivalent Vaccine in the Public Healthcare Sector

    Dec 1, 2023, 00:00

  • HTA361 Living Systematic Review (LSR) in Health Technology Assessment (HTA): Current Guidance, Methods, and Challenges

    Dec 1, 2023, 00:00

  • EE398 Economic Burden of Wilson's Disease: A Systematic Review

    Dec 1, 2023, 00:00

  • HTA310 Evolution of French Economic Opinions Published By the Economic Evaluation and Public Health (CEESP) in Oncology

    Dec 1, 2023, 00:00

  • RWD26 Dupixam: An Algorithm to Identify Patients with Atopic Dermatitis Among Dupilumab-Treated Population Using the SNDS (SYSTEME NATIONAL DES DONNEES DE SANTE) in France

    Dec 1, 2023, 00:00

  • EE361 From Biobank Sample to Breast Cancer Prevention—Cost-Effectiveness Analysis of Returning Genomic Data to Sample Donors

    Dec 1, 2023, 00:00

  • Advancements in Digital Health Interventions: Evidence Syntheses, Value Assessment, and Global Perspectives

    Dec 1, 2023, 00:00

  • HTA157 Reflection on Medicines That Have Recently Come Off Patent and Have Been Rejected by NICE in the Past 20 Years: A Case Study of Abiraterone for Treating Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPC)

    Dec 1, 2023, 00:00

  • EE522 Cost-Effectiveness of Direct Oral Anticoagulants (DOACS) Versus Low-Molecular-Weight Heparins (LMWH) in Patients with Cancer-Associated Venous Thromboembolism (CAT) in Hong Kong

    Dec 1, 2023, 00:00

  • EE82 A Cost-Utility Analysis of the MyPal eHealth Application, an ePro Intervention Aiming to Foster Palliative Care of Cancer Patients: Results From a Randomized Clinical Trial in 4 European Countries

    Dec 1, 2023, 00:00

  • PT3 Concept Elicitation Interviews to Refine a Conceptual Model of the Patient Experience of Amyotrophic Lateral Sclerosis (ALS)

    Dec 1, 2023, 00:00

  • Preferences for Palliative and End-of-Life Care: A Systematic Review of Discrete Choice Experiments [Editor's Choice]

    Dec 1, 2023, 00:00

  • MT50 Real-World Utilization and Outcomes of Transcatheter Mitral Valve Leaflet Repair (TMVLR) in Asian Patients with Mitral Regurgitation: A Singapore Experience

    Dec 1, 2023, 00:00

  • HSD89 The Operational Effectiveness of Using an M L-Driven Patient Medical Record: A Simulated Comparative Study Using Real-World Data

    Dec 1, 2023, 00:00

  • PCR128 A Systematic Literature Review of Patient-Reported Outcomes With Nivolumab Across Gastric and Oesophageal Cancers

    Dec 1, 2023, 00:00

  • PCR137 Understanding the Signs, Symptoms and Impacts of Metachromatic Leukodystrophy (MLD)

    Dec 1, 2023, 00:00

  • HTA241 Health Equity and the Health Technology Assessment Process: Are Children and Young People Being Overlooked? A Review of Pediatric National Institute of Health and Care Excellence Technology Appraisals

    Dec 1, 2023, 00:00

  • CO91 Association Between Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)

    Dec 1, 2023, 00:00

  • HTA103 Systematic Literature Reviews to Identify Clinical and Economic Outcomes in Adults With Pompe Disease

    Dec 1, 2023, 00:00

  • EPH199 Factors Associated With Hospitalization for E-Cigarette/Vaping Associated Lung Injury (EVALI) in the United States

    Dec 1, 2023, 00:00

  • EE371 Economic Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors Compared with Standard Chemotherapy in Thailand

    Dec 1, 2023, 00:00

  • HPR24 Utilisation and Expenditure on Blood Glucose Test Strips in Ireland—The Impact of Health Technology Management in Reducing and Containing Expenditure

    Dec 1, 2023, 00:00

  • HTA180 Analyzing Transparency Committee Discussions: A Database Approach to Understanding Decision-Making Factors

    Dec 1, 2023, 00:00

  • EE718 Cost-Effectiveness of Medical Cannabis for Treatment of Chronic Pain: A Longitudinal Cohort Study of a Large German Hybrid Telemedicine Platform

    Dec 1, 2023, 00:00

  • HTA142 Evolution of French Economic Opinions Published by the Economic Evaluation and Public Health Committee (CEESP)

    Dec 1, 2023, 00:00

  • PCR174 The Patient-Centered Core Impact Set Taxonomy: A Practical Example of Use and Refinement Using Voice-of-the-Patient Reports and Patient Interviews

    Dec 1, 2023, 00:00

  • EE84 Healthcare Resource Use and Cost in Metastatic Castration Resistant Prostate Cancer (mCRPC) in Finland

    Dec 1, 2023, 00:00

  • CO126 Effectiveness of Cell-Based Treatment Compared to Current Standard of Care for Knee Osteoarthritis Patients in the Netherlands

    Dec 1, 2023, 00:00

  • EPH266 Mechanisms of HPV Vaccine Knowledge Levels Under Restricted Supply of Nine-Valent Vaccine in China Mainland

    Dec 1, 2023, 00:00

  • HPR129 Catastrophic Health Expenditure: A Comparative Analysis of in Elderly Household and Non-Elderly Household in Korea

    Dec 1, 2023, 00:00

  • EE437 Cost-Utility Analysis of Acupotomy with Nerve Block Therapy from Lumbosacral Radiculopathy Patients in Korea

    Dec 1, 2023, 00:00

  • CO156 Direct Oral Anticoagulants in Adults with Non-Valvular Atrial Fibrillation: Systematic Review and Network Meta-Analysis of Real-World Evidence

    Dec 1, 2023, 00:00

  • HTA283 A Scoping Review of Health Technology Assessment Agency (HTA) and Health Economic (HE) Modelling Guidelines for Identification of Health Economic Model Inputs

    Dec 1, 2023, 00:00

  • HSD41 Healthcare Models for Rare Diseases: A Systematic Literature Review for the Development of a Comprehensive Model in a Latin American Country

    Dec 1, 2023, 00:00

  • MSR113 Inferring the Proportion of Durable Responders to Targeted Oncology Therapies in Combination Regimens Using Bayesian Parametric Mixture Survival Models

    Dec 1, 2023, 00:00

  • EE14 Cost Effectiveness of Sensor Augmented Pump Therapy with Automated Insulin Suspension in the Management of Type 1 Diabetes (T1D) in Bulgaria

    Dec 1, 2023, 00:00

  • EPH141 The Impact of Short Bowel Syndrome in Adult Patients in Portugal

    Dec 1, 2023, 00:00

  • EPH76 Triptan Switches for Danish Migraine Patients Treated With at Least Three Distinct Triptans Before Discontinuation—A Register Based Study

    Dec 1, 2023, 00:00

  • MSR18 Modelling Challenges in Geographic Atrophy

    Dec 1, 2023, 00:00

  • RWD117 Comparison the Annual, Nationwide Health Insurance Treatment Cost of Hip Osteoarthritis Based on Routinely Collected Financing Data in 2010 and 2018 in Hungary

    Dec 1, 2023, 00:00

  • SA26 Prevalence and Burden of Lupus in Adult French Population: A Retrospective Longitudinal National Hospital Claims Study

    Dec 1, 2023, 00:00

  • SA23 Bruton Tyrosine Kinase Inhibitor (BTKi) Monotherapy for the Treatment of ‘High-Risk’ Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • EE699 Economic Burden of Propionic Acidemia by Age Stratum in the United States

    Dec 1, 2023, 00:00

  • EE702 Humanistic and Economic Burden of Methylmalonic Acidemia—A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EPH156 Modelling Herpes Zosters Burden and Public Health Impact of Adjuvanted Recombinant Zoster Vaccine Among Adults Aged ≥50 Years Old in Seven Countries in Central and South America

    Dec 1, 2023, 00:00

  • EE703 Economic Burden and Changing Treatment Landscape in Stargardt Disease: A Literature and Database Review

    Dec 1, 2023, 00:00

  • EE451 Methods to Measure the Environmental Impacts of Health Technologies and to Include Them in Economic Evaluations: A Scoping Literature Review

    Dec 1, 2023, 00:00

  • EE494 Optimizing Treatment of Schizophrenia: Pharmacoeconomic Consequences and Potential for Patient Switching to Long-Acting Injectables

    Dec 1, 2023, 00:00

  • MSR75 Correlate: Assessing Dose Effect Using Targeted Maximum Likelihood Estimation (TMLE)

    Dec 1, 2023, 00:00

  • EE431 Evaluating the Budget Impact of NOVOCART Inject Plus (Ninject) for Symptomatic Knee Cartilage Defects in the NHS

    Dec 1, 2023, 00:00

  • HTA297 The Inclusion of Caregiver Burden in the National Institute for Health and Care Excellence (NICE) Health Technology Appraisals (HTAS) of Treatments for Mental Health Disorders

    Dec 1, 2023, 00:00

  • EPH268 Effectiveness of Pneumococcal Vaccination in Older Adults in a Real-World Setting: A Systematic Review and Meta-Analysis of Observational Studies Using Test-Negative Designs

    Dec 1, 2023, 00:00

  • EE177 Cost-Effectiveness Modelling in Moderate to Severe Ulcerative Colitis: Novel Approaches to Capture Variable Induction Periods, Treatment Sequences, and Variable Treatment Cycle Lengths

    Dec 1, 2023, 00:00

  • CO133 Systematic Literature Review (SLR) of Clinical Data from First-Line Treatment or First-Line Maintenance Therapy for Advanced or Metastatic Ovarian Cancer (2010–2023)

    Dec 1, 2023, 00:00

  • EPH52 Survey of Situation and Severity of Public Problems Affecting Health in an Industrial District in Thailand

    Dec 1, 2023, 00:00

  • EE436 Economic Evaluation of Transcatheter Versus Surgical Aortic Valve Replacement in Low- and Intermediate-Risk Patients with Severe Aortic Stenosis in China

    Dec 1, 2023, 00:00

  • EPH20 Muscular Dystrophy-Related Hospitalizations and Outpatient Procedures in the Brazilian Public Healthcare System: A Real World Data Analysis

    Dec 1, 2023, 00:00

  • EE511 Systematic Review of Cost Effectiveness Assessment Reports of Immune Checkpoint Inhibitors in Early and Advanced/Metastatic Stages of Cancer in France

    Dec 1, 2023, 00:00

  • EE135 Efficiency Management of Immunization Programs in Peru, in the Context of the COVID-19 Pandemic: The Fully Liquid Acellular Hexavalent Vaccine

    Dec 1, 2023, 00:00

  • EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden

    Dec 1, 2023, 00:00

  • EE272 Cost-Effectiveness of Voclosporin in Combination with Mycophenolate Mofetil for Active Lupus Nephritis in Sweden

    Dec 1, 2023, 00:00

  • PCR180 The Life with Myasthenia Gravis: Socioeconomic Impact of the Disease on Patients in the Czech Republic

    Dec 1, 2023, 00:00

  • Clinical Outcomes

    Dec 1, 2023, 00:00

  • PCR195 Patient Voice in Smc Technology Appraisals for Orphan and Ultra-Orphan Diseases

    Dec 1, 2023, 00:00

  • EE596 Cost-Effectiveness and Public Health Impact of a Nine-Valent Human Papillomavirus Vaccination Program in Ukraine

    Dec 1, 2023, 00:00

  • EE452 Comparison of Disease Agnostic Healthcare Resource Utilization and Costs Across the US and EU5 Population

    Dec 1, 2023, 00:00

  • RWD27 Opportunities and Challenges in Linkage of Early Access Databases With the French National Claims Database: A RWE Effectiveness Study of AZD7442 for Pre-Exposure Prophylaxis Against COVID-19 in Immunocompromised Patients

    Dec 1, 2023, 00:00

  • EE738 Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension: An Analysis for Sweden Based on the SPYRAL HTN-ON MED Trial and Other Contemporary Evidence

    Dec 1, 2023, 00:00

  • EE664 Total Direct Costs of Ovarian Cancer in Colombia: A National Cohort Study Based on Administrative Claims Databases

    Dec 1, 2023, 00:00

  • EE758 Modelling Visual Acuity Distributions to Inform a Simplified Cost Effectiveness Analysis

    Dec 1, 2023, 00:00

  • EPH218 Knowledge of Contraception and Sexually Transmitted Diseases Regarding the Quality of Education and Parent-Child Relationship Among Secondary School Students

    Dec 1, 2023, 00:00

  • HTA307 Evolving Principles for Defining and Assessing the Economic and Societal Value of Cancer Therapies

    Dec 1, 2023, 00:00

  • HSD14 X-Linked Retinitis Pigmentosa Impacts Patients’ Independence, Work Status, and Quality of Life: Insights from the Cross-Sectional Explore Xlrp-1.2 Physician Survey

    Dec 1, 2023, 00:00

  • EPH32 Canadian Pustular Psoriasis Study (CAPPS): Examining Disease Burden, Treatments, and Healthcare Resource Utilization for Generalized Pustular Psoriasis Flares

    Dec 1, 2023, 00:00

  • HPR79 Analysis of Newly FDA Approved Medicines and the Licensing Status By Titck in Turkiye

    Dec 1, 2023, 00:00

  • MSR133 What Factors Influence the Prescription of Oral Antivirals for COVID-19 in Japan? – a State Transitional Agent-Based Model Analysis

    Dec 1, 2023, 00:00

  • EE140 Comparison of the Clinical and Economic Impact of Two MRNA COVID-19 Vaccines in High Risk Individuals in Japan

    Dec 1, 2023, 00:00

  • EE353 Incorporation of Cladribine for Patients With Multiple Sclerosis in a Health Insurance Company in Brazil: Cost-Effectiveness

    Dec 1, 2023, 00:00

  • RWD178 Real-World Evidence in Post-Authorization Studies: Review of European Databases in the ENCePP EU Pas Register® Between 2010 – 2023

    Dec 1, 2023, 00:00

  • PCR160 An Integrated Software Platform to Capture Patient Preference Data Throughout the Medical Product Lifecycle

    Dec 1, 2023, 00:00

  • RWD121 Moment Registry (MET NON SMALL CELL CANCER REGISTRY) for Advanced Non-Small Cell Lung Cancer (ANSCLC) Harboring MET Exon 14 (METEX14) Skipping

    Dec 1, 2023, 00:00

  • MSR112 Assessing the Feasibility of Applying Natural Language Processing for Systematic Literature Reviews: A Case Study in Non-Small-Cell Lung Cancer

    Dec 1, 2023, 00:00

  • PCR14 Prioritization of Social Disability Management Using a Patient Reported Outcome Questionnaire in Patients Suffering from Multiple Sclerosis (MS)

    Dec 1, 2023, 00:00

  • EPH219 The Effect of Gestational Weight Gain on Pregnancy Outcome

    Dec 1, 2023, 00:00

  • EE741 Costs of Breast Surgery Reconstruction and Mastectomy in France between 2019 and 2021

    Dec 1, 2023, 00:00

  • CO191 Effectiveness of New Generation Heat and Moisture Exchangers and Adhesives for Laryngectomized Patients in Portugal

    Dec 1, 2023, 00:00

  • EE463 Economic Evaluation of Single Pill Combination Clopidogrel: Aspirin Versus Free Combination Clopidogrel Plus Aspirin for Prevention of Cardiovascular Events After Acute Coronary Syndrome in China

    Dec 1, 2023, 00:00

  • Cover

    Dec 1, 2023, 00:00

  • MSR93 Hype, Not Hope: Using Bayesian Methods in Drug Development

    Dec 1, 2023, 00:00

  • EE326 Cost-Effectiveness of Multiparametric MRI (mpMRI) Compared to No Test for Monitoring of NASH Treatment in the UK

    Dec 1, 2023, 00:00

  • EE173 Budget Impact Analysis of IDegAsp for the Management of Type 2 Diabetes in Saudi Arabia

    Dec 1, 2023, 00:00

  • SA55 Whole-Body MRI Accuracy and Cost-Effectiveness Compared with Standard Pathways for Detecting and Monitoring Bone Metastases in Prostate Cancer: A Systematic Review

    Dec 1, 2023, 00:00

  • EE46 BoNT-As for Cervical Dystonia: Cost of Treatment and Response to Therapy in Canadian Patients

    Dec 1, 2023, 00:00

  • CO64 Challenges Associated with Surrogate Endpoints for Healthcare Decision Making in Oncology

    Dec 1, 2023, 00:00

  • HTA248 Incorporating Patient Perspectives in HTA Assessments for Rare Diseases: Insights From Multiple HTA Assessments

    Dec 1, 2023, 00:00

  • EPH48 Targeted Influenza Vaccination in at Risk Populations – How Avoided Cases Translate into Clinical and Economic Benefits for Czech Republic, Hungary, and Romania

    Dec 1, 2023, 00:00

  • HSD72 Improving Patient Care for Chronic Kidney Disease-Related Anemia in Italy: A Survey to Evaluate the Nephrological Card As a Tool for Optimizing Treatment Pathway

    Dec 1, 2023, 00:00

  • HPR108 Managed Entry Agreements and Appropriateness Tools Over the Last Three Years in Italy

    Dec 1, 2023, 00:00

  • EE548 Data Availability and Modelling Approaches in Health Economic Evaluation of Cystic Fibrosis: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • CO90 Augmenting Synthetic Control Arms Using Bayesian Borrowing: A Case Study in First-Line Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • MT25 What Evidence Should Medical Technology Companies Expect HTA Bodies to Review?

    Dec 1, 2023, 00:00

  • HPR23 Preparing Healthcare Systems for Broader Cell Gene Therapy (CGT) Access: What Needs to Change for Pharma, Healthcare Systems, and Patients so All Benefit From CGTs?

    Dec 1, 2023, 00:00

  • HTA268 Key Issues in the Methods and Process of Health Technology Assessment in China: A National Expert Survey

    Dec 1, 2023, 00:00

  • MSR95 Simulated Treatment Comparison or Matching-Adjusted Indirect Comparison: Which Wins in the Battle for Prominence and Validity in Population-Adjusted Indirect Treatment Comparison?

    Dec 1, 2023, 00:00

  • EE622 Improved Glycemic Outcomes and Associated Cost Savings with an Advanced Hybrid Closed Loop System for People with Type 1 Diabetes with Suboptimal Glycemic Control in Europe

    Dec 1, 2023, 00:00

  • HTA64 Surrogate Endpoints Used in NICE Technology Appraisals for Oncology and Non-Oncology Indications, 2022–23

    Dec 1, 2023, 00:00

  • EE322 A Cost Analysis for Macrovascular Events, Comparison of Glargine 300U/Ml (GLA-300) and Degludec 100U/Ml (IDeg-100) in the Treatment of Type 2 Diabetes Mellitus in Older Population or Renal Impairment Individuals in Latin America

    Dec 1, 2023, 00:00

  • MSR159 A Novel Unanchored Simulated Treatment Comparison Approach for Time-to-Event Data

    Dec 1, 2023, 00:00

  • An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021

    Dec 1, 2023, 00:00

  • CO165 Validation of High Risk Criteria in Medication Reconciliation in Major Orthopedic Surgery: A Delphi Study

    Dec 1, 2023, 00:00

  • HTA149 Handling Uncertainty in Health-Economic Assessments: Experience From COVID-19 in France

    Dec 1, 2023, 00:00

  • EPH182 Factors Associated with Augmentation Agent Use in Patients with Treatment-Resistant Depression

    Dec 1, 2023, 00:00

  • HTA159 Review of Survival Modeling Approaches Adopted in NICE Technology Appraisals (TAs) in Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • EPH26 Assessing Cancer Related Premature Mortality and Productivity Loss in Lung, Melanoma, and Breast Cancers in European Regions: Temporal Trends in 2010-2019

    Dec 1, 2023, 00:00

  • PCR63 Health-Related Quality of Life in COVID-19: A Vignette Study

    Dec 1, 2023, 00:00

  • EE547 The Societal Costs of Metachromatic Leukodystrophy (MLD) in the United States

    Dec 1, 2023, 00:00

  • EE426 The Acceptance of Indirect Treatment Comparisons in Pharmacoeconomic Analyses by the Dutch Healthcare Institute (ZIN)

    Dec 1, 2023, 00:00

  • HSD115 Genetic Testing in Chinese Breast Cancer Patients: A Survey on Knowledge, Receipt, and Willingness to Pay

    Dec 1, 2023, 00:00

  • HTA316 Understanding the Application of Various Statistical Analysis Methods to Inform Comparative Effectiveness of Ultra Orphan Treatments: A Review of NICE HST Guidance

    Dec 1, 2023, 00:00

  • EPH113 Assessment of the Quality of Life in Patients With Acute Ischemic Stroke Diagnosed With Brainomix Artificial Intelligence-Based System, Under Different Therapeutic Approaches (Standard Treatment, Thrombolysis, Thrombectomy)

    Dec 1, 2023, 00:00

  • HSD42 The Humanistic Impact of X-Linked Retinitis Pigmentosa (XLRP): Results from the Explore Xlrp-2 Retrospective Chart Review and Cross-Sectional Survey of Patients and Caregivers in 10 Countries

    Dec 1, 2023, 00:00

  • MSR155 Identifying Relevant Clinical Regulatory and Health Technology Assessment (HTA) Precedents via Artificial Intelligence (AI)

    Dec 1, 2023, 00:00

  • MSR101 Methodological Insights on Indirect Treatment Comparisons for Ulcerative Colitis Therapies in NICE Submissions

    Dec 1, 2023, 00:00

  • RWD165 Improving Evidence Generation From Rare Disease Registries: Performing Variable Gap Analyses

    Dec 1, 2023, 00:00

  • HPR76 Financial Feasibility Study of Incremental Modified Drugs Development by Domestic Pharmaceutical Industry

    Dec 1, 2023, 00:00

  • PCR170 The Prevalence and Factors That Affect Perceived Stress, Anxiety, and Depression Among IBD Patients

    Dec 1, 2023, 00:00

  • RWD124 Characteristics of Patients with Advanced Endometrial Cancer Who Received Pembrolizumab As Part of an Early Access Program (EAP) in Accordance with KN-775 Labelling

    Dec 1, 2023, 00:00

  • EE100 Costs of Home Mechanical Ventilation and Oxygen Therapy in Russia: Real-World Data

    Dec 1, 2023, 00:00

  • CO136 Systematic Literature Review (SLR) of Clinical Data in Third-Line and Beyond (3L+) Small Cell Lung Cancer (SCLC) Patients

    Dec 1, 2023, 00:00

  • EPH142 Fibrodysplasia Ossificans Progressiva (FOP): Prevalence Estimate By Hospitalization Data

    Dec 1, 2023, 00:00

  • EE121 Cost-Efficiency and the Opportunity for Expanded Treatment Access with Incremental Increases in Biosimilar Adalimumab and Tocilizumab Use: A European Perspective

    Dec 1, 2023, 00:00

  • EE51 Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations

    Dec 1, 2023, 00:00

  • HTA364 Can Artificial Intelligence and Machine Learning Be Used to Demonstrate the Value of a Technology for HTA Decision-Making?

    Dec 1, 2023, 00:00

  • EPH72 Polysubstance Use of Psychoactive Stimulants, Suicidal Behavior, and Mental Health Disability Among Women of Reproductive Age

    Dec 1, 2023, 00:00

  • EE602 Examination of Changes Experienced in Prices of Goods and Services That Affect Manufacturing Costs in Health Industry for Slovenia

    Dec 1, 2023, 00:00

  • EE196 Real World Evidence on the Burden of Disease for Patients and Their Nearest Relatives - the Case of Duchenne Muscular Dystrophy

    Dec 1, 2023, 00:00

  • EPH240 Epidemiology, Economic Burden, and Humanistic Burden in Multiple Sclerosis Spasticity (MSS): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • PCR203 A Qualitative Study of the Health-Related Quality of Life Impact of Geographic Atrophy on Patients

    Dec 1, 2023, 00:00

  • CO96 Myelofibrosis Symptom Assessment Form Total Symptom Score (MFSAF TSS) v4.0: Measurement Properties from the Momentum Phase 3 Study

    Dec 1, 2023, 00:00

  • MSR141 Identifying and Extrapolating Immature OS Data in Survival Analysis: A Review of the Variation in Methods Used in Oncology STAs for NICE

    Dec 1, 2023, 00:00

  • HTA348 How to Align EU HTA with National Market Access?

    Dec 1, 2023, 00:00

  • CO174 Real World Data of Daratumumab Treatment in Patient with Multiple Myeloma: A Portuguese Study

    Dec 1, 2023, 00:00

  • EE731 Estimating the Economic Impact of Enabling the Digital Transfer of Patients’ Prescription Information in the English National Health Service

    Dec 1, 2023, 00:00

  • P35 How Perspective Affects the Cost-Effectiveness of Remote Patient Monitoring for Patients With Heart Failure in Different European Countries

    Dec 1, 2023, 00:00

  • HPR171 WTP Threshold: A Review of International Approaches and Inspiration for Cultivation of Current Situation in the Czech Republic

    Dec 1, 2023, 00:00

  • MSR50 Comparing Treatment Options for Fabry Disease: Feasibility Assessment for Network Meta-Analysis (NMA)

    Dec 1, 2023, 00:00

  • EE394 Understanding Reasons of Negative Reimbursement Decisions for Orphan Drugs in the Spanish National Health System (APRIL 2019-MAY 2023)

    Dec 1, 2023, 00:00

  • HPR160 An Ecological Study of 4 Drug Categories Consumption Inequities in Spain

    Dec 1, 2023, 00:00

  • RWD141 How Global Datasets Can Shed Light on Health Inequalities: An Environmental Scan of Publicly Available Sources

    Dec 1, 2023, 00:00

  • PCR113 EQ-5D Studies in Pediaric Diabetes: A Systematic Review

    Dec 1, 2023, 00:00

  • EE245 Indirect Cost of Spinal Muscular Atrophy (SMA) in Singapore

    Dec 1, 2023, 00:00

  • PCR34 The Humanistic and Economic Burden of Illness in Progressive Fibrosing Idiopathic Lung Disease: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • RWD54 Real-World Evidence for Patient Outcomes and Mutational Burden in Non-Small Cell Lung (NSCLC) Cancer Patients in England Using EGFR Biomarker Test Data from Routine Clinical Care

    Dec 1, 2023, 00:00

  • EE412 Unraveling the Disease Burden of Generalized Pustular Psoriasis: A Comparative Analysis of Flares with Psoriasis Vulgaris in Taiwan

    Dec 1, 2023, 00:00

  • HTA240 An Evaluation of the Reimbursement Status of CAR-T Cell Therapies in the EU-4 and UK

    Dec 1, 2023, 00:00

  • HTA334 Assessment of Vaccines in Europe, the HPV Example: Can the EU Joint Clinical HTA Regulation Result in More Consistent Vaccine Evaluations and Improve Access Across EU Countries?

    Dec 1, 2023, 00:00

  • EE659 Estimating the Economic Consequences of Migraine in Sweden: A Fiscal Model Using the Government Perspective of Costs

    Dec 1, 2023, 00:00

  • EE307 Drive-the-Doctor Paradigm for Acute Ischemic Stroke with Large Vessel Occlusion: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • EE305 Cost-Effectiveness Analysis of Genetic Screening in First-Degree Relative of Hypertrophic Cardiomyopathy Patients From the Perspective of the Brazilian United Health System

    Dec 1, 2023, 00:00

  • RWD86 Characteristics of Patients with Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Who Received Pembrolizumab as Part of an Early Access Program in Accordance with KN-355 Labelling

    Dec 1, 2023, 00:00

  • PCR250 Management of Osteogenesis Imperfecta: Self-Reported Funding Sources for Healthcare, Consumables and Services Across the EU5 and Nordics

    Dec 1, 2023, 00:00

  • EE53 An Investigation of Value for Money of Oncology Drugs in Canada

    Dec 1, 2023, 00:00

  • HTA182 The EU Regulation on HTA: Developing an Adapted Market Access Framework for Pharmaceutical Assets

    Dec 1, 2023, 00:00

  • EE363 Cost-Effectiveness Analysis of Adding Tumor Treating Fields Therapy to Temozolomide Versus Temozolomide Only in Patients with Glioblastoma in France

    Dec 1, 2023, 00:00

  • HSD82 Impact of the COVID-19 Pandemic in the Netherlands on Primary Healthcare Use and Clinical Outcomes in People with Type 2 Diabetes

    Dec 1, 2023, 00:00

  • EPH214 Estimating the Burden of Vaccine-Preventable Insect-Borne Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?

    Dec 1, 2023, 00:00

  • OP13 Impact of Pay-for-Performance Programs on Diabetes Management: A Critical Analysis

    Dec 1, 2023, 00:00

  • CO6 Teduglutide for Treating Short-Bowel Syndrome in Adults: A Meta-Analysis of Real-World Evidence Compared to Clinical Trial Data

    Dec 1, 2023, 00:00

  • Health Policy Regulatory

    Dec 1, 2023, 00:00

  • HTA242 Incorporating Health Inequalities (HIs) Considerations into United Kingdom (UK) HTA Decision Making and the Impact on Rare Disease Medicines

    Dec 1, 2023, 00:00

  • EE67 Insurer and Patient Costs for Repeat Breast Surgery After Initial Lumpectomy for Breast Cancer

    Dec 1, 2023, 00:00

  • HTA66 Review and Analysis of Economic Model Characteristics According to Published HTA Conclusions in Ukraine

    Dec 1, 2023, 00:00

  • CO15 Clinical Outcomes of Patients with Relapsed/Refractory Large B-Cell Lymphoma Receiving Second-Line Therapy in England: A Multicenter, Retrospective, Real-World Study

    Dec 1, 2023, 00:00

  • HPR146 Fit for Purpose Policy Recommendations Related to Funding, Pricing, and Procurement of Point-of-Care Tests Used in Patients With Respiratory Tract Infections

    Dec 1, 2023, 00:00

  • PCR241 The Experience of Patients Living with Multiple Myeloma: Unmet Needs Associated with Diagnosis, Treatment, and Living with the Condition

    Dec 1, 2023, 00:00

  • HTA195 Optimized Recommendations in NICE Technology Appraisals: Permissive or Restrictive?

    Dec 1, 2023, 00:00

  • HTA329 The Race to Improve Health Technology Assessment of Gene Therapies: Which Countries Are Embracing Recommendations?

    Dec 1, 2023, 00:00

  • EPH23 Diagnosis Patterns in Breast Cancer Women in Brazil: Inequities Among Public and Private Settings in São Paulo State

    Dec 1, 2023, 00:00

  • EPH146 Epidemiological Insights in Cutaneous Lupus Erythematosus: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE544 The Impact of Pulmonary Arterial Hypertension in the Brazilian Public Healthcare System: A Microcosting Approach Based on Expert's Opinion

    Dec 1, 2023, 00:00

  • Health Technology Assessment

    Dec 1, 2023, 00:00

  • MSR116 Unsupervised Clustering and Binary Classification Analysis for Predicting Long COVID Among Adults in EU4 and UK

    Dec 1, 2023, 00:00

  • MSR110 Four Alternative Methodologies for Simulated Treatment Comparison: How Could the Use of Simulation be Re-Invigorated

    Dec 1, 2023, 00:00

  • CO187 Relative Effectiveness of Faricimab Vs Aflibercept 8 Mg after Loading Phase in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

    Dec 1, 2023, 00:00

  • EE677 Cost-Consequence of Using NGS vs Single-Testing in NSCLC Patients at Diagnosis – Real-World Data From a Portuguese Hospital

    Dec 1, 2023, 00:00

  • SA73 A Retrospective Cohort Study to Evaluate the Disease Burden, Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Breast Cancer in Dubai, United Arab Emirates

    Dec 1, 2023, 00:00

  • RWD123 The Impact of COVID-19 on Treatment of Patients With Ovarian Cancer in England

    Dec 1, 2023, 00:00

  • HTA147 Similarities and Differences Between the HTA Methods for Indirect Comparisons in the EU Joint Clinical Assessment and National Assessments by Member States

    Dec 1, 2023, 00:00

  • SA54 Quality of Life, Economic Burden, and Comorbidities Associated with Essential Tremor: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • MSR5 Accuracy of Automated Data Extraction for Systematic Literature Reviews

    Dec 1, 2023, 00:00

  • RWD115 Assessing and Comparing Inpatient Hospitalization for Mental Disorders in the United States and European OECD Countries

    Dec 1, 2023, 00:00

  • EE227 Waldenstrom's Macroglobulinemia: An Overview of Treatment Patterns, Resource Use, and Costs From the Brazilian Private Healthcare Perspective

    Dec 1, 2023, 00:00

  • EE689 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment (Monotherapy) for Adult Patients With Non-Small Cell Lung Cancer Following Resection and Platinum-Based Chemotherapy in Greece

    Dec 1, 2023, 00:00

  • Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach

    Dec 1, 2023, 00:00

  • SA38 Out-of-Pocket Expenses and Lost Earnings for Breast Cancer Patients Undergoing Treatment: Evidence From the UK Persephone Randomised Controlled Trial Abstract

    Dec 1, 2023, 00:00

  • EE34 Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Meropenem for the Treatment of Serious Infections Due to Gram-Negative Bacteria for Which There Are Limited Treatment Options (LTO) in Italy

    Dec 1, 2023, 00:00

  • RWD155 Using Real-World-Evidence to Inform Pathway Evaluations at NICE: Benefits and Challenges

    Dec 1, 2023, 00:00

  • EPH130 Drug Utilization Patterns of Guanfacine Hydrochloride Indicated for Attention Deficit Hyperactivity Disorder in European Countries

    Dec 1, 2023, 00:00

  • RWD135 A Demographic Description of Women With Uncomplicated Urinary Tract Infection in England: A Primary Care Electronic Health Records and Notes Review

    Dec 1, 2023, 00:00

  • EE349 The Impact of Using Real-World Data on the Cost-Effectiveness of Fremanezumab for Migraine Prevention in a UK Healthcare Perspective Analysis

    Dec 1, 2023, 00:00

  • MT66 Characteristics of Patients with Symptomatic Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Implantation (TAVI): A Real-World Study in Singapore

    Dec 1, 2023, 00:00

  • EE300 Looking Sharp! Applying Cutting-Edge Shapley Additive Explanation (SHAP) Approaches to Cost-Effectiveness Modelling in Contrast to One-Way Sensitivity Analysis

    Dec 1, 2023, 00:00

  • MT8 Assessing Feasibility of Socially Assistive Humanoid Robots in Assisting in Nursing Routine

    Dec 1, 2023, 00:00

  • OP16 Environmental Sustainability Success Stories From the Pharmaceutical and Medtech Industries in Europe: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • RWD112 Factors Associated with High Costs of Patients with Non-Alcoholic Fatty Liver Disease: An Observational Study Using the French Constances Cohort

    Dec 1, 2023, 00:00

  • PCR24 Patient and Caregiver Perceptions of Systemic Anticancer Treatments in Advanced Bladder Cancer (aBC): Results of a Social Media Listening (SML) Study Conducted in 5 European Countries (Eu5)

    Dec 1, 2023, 00:00

  • EE690 Assessing the Relative Budget Impact (BI) of PARP Inhibitor (PARPi) Combination Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) with and Without BRCA1/2 Mutations

    Dec 1, 2023, 00:00

  • SA77 Health Technology Assessment (HTA) Feasibility Study: The XprESS Device for the Treatment of Patients With Eustachian Tube Dysfunction

    Dec 1, 2023, 00:00

  • EE58 Endometrial Cancer Care in Colombia: A Cost-of-Illness Study Based on Administrative Claims Databases

    Dec 1, 2023, 00:00

  • PCR56 Is Walking As Important As Muscle Strength After Stroke? Preference Weighting of ICF's Core Elements

    Dec 1, 2023, 00:00

  • HTA239 Network Meta-Analysis on the Efficacy and Safety of Drugs for the Treatment of Acute Myeloid Leukemia in the Elderly

    Dec 1, 2023, 00:00

  • SA39 Targeted Treatments for Patients with Relapsed and/or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR) of Randomized Clinical Trials (RCTs)

    Dec 1, 2023, 00:00

  • EE306 Utilizing Real World Evidence for Cost-Effectiveness Analysis of the Disease Management Program for Chronic Heart Failure Herzmobil Tirol

    Dec 1, 2023, 00:00

  • EE674 Healthcare Resource Use and Costs Associated with Endometrial Cancer Treatment in the Private Setting in Brazil

    Dec 1, 2023, 00:00

  • RWD166 Assessment of Haemophilia Management in Algeria: Challenges and Perspectives

    Dec 1, 2023, 00:00

  • PCR103 Validating an Herpes Zoster Health Related Quality of Life Conceptual Model in Argentina: Literature Review and Qualitative Study

    Dec 1, 2023, 00:00

  • HPR94 Treating Early Often Comes Too Late: Ensuring Patient Access to Early Cancer Detection and Treatment in Europe

    Dec 1, 2023, 00:00

  • HTA306 The Combination Conundrum: Comparing Reimbursement Outcomes for Oncology Combination Products in the UK and France

    Dec 1, 2023, 00:00

  • MT29 Understanding How Health Technology Assessment Bodies Select Medical Technology for Review: Results of an Online Survey

    Dec 1, 2023, 00:00

  • EPH86 Access to a First Disease-Modifying Therapy Leads to a Disproportionate Increase in the Patient Population Diagnosed with a Rare Disease

    Dec 1, 2023, 00:00

  • EE362 A Budget Impact Analysis of Pertuzumab, Trastuzumab, and Chemotherapy in the Neoadjuvant Setting for HER2-Positive High-Risk Early Breast Cancer Patients: Insights from the Tuscany Regional Health Care System Perspective

    Dec 1, 2023, 00:00

  • HPR145 Access of Rare Disease Treatments in the Nordics

    Dec 1, 2023, 00:00

  • MSR131 Prospects for Automation of Systemic Literature Reviews (SLRs) With Artificial Intelligence and Natural Language Processing

    Dec 1, 2023, 00:00

  • EE556 Beclometasone/Formoterol/Glycopyrronium Vs. Fixed and Open Combinations of Inhaled Corticosteroids, Long-Acting B2-Agonist, and Long-Acting Muscarinic Antagonist in Adults with Uncontrolled Asthma: A Network Meta-Analysis

    Dec 1, 2023, 00:00

  • PT10 Opioid Tapering and Its Associations with Risk of Opioid Use Disorder and Mortality Among Older Adults

    Dec 1, 2023, 00:00

  • HSD79 Assessment of Patient Satisfaction with Public Pharmacies Dispensing High-Cost Drugs in Greece

    Dec 1, 2023, 00:00

  • EPH140 Prevalence Estimation of Thymidine Kinase 2 Deficiency: An Ultra-Rare Autosomal Recessive Mitochondrial Disease

    Dec 1, 2023, 00:00

  • SA45 Natural Evolution of Chronic Kidney Disease in Diabetic Patients: Costs and Consequences in Portuguese Reality

    Dec 1, 2023, 00:00

  • EE372 Modeling the Cost-Effectiveness in a Sub-Population: Tepotinib Versus Chemoimmunotherapy (C+IO) in Untreated Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METEX14) Skipping

    Dec 1, 2023, 00:00

  • EE504 Buprenorphine–Naloxone Film Yields Cost Savings in Administration Time Compared With Sublingual Tablets in Sweden

    Dec 1, 2023, 00:00

  • HTA189 A Critical Appraisal of Economic Evaluations in RSV

    Dec 1, 2023, 00:00

  • PT36 Real-World Analysis on Therapeutic Pattern and Economic Burden of Androgen-Receptor Signaling Inhibitors (ARSI) and Taxane-Based Chemotherapy Treated Metastatic Castration-Resistant Prostate Cancer Patients in Italy

    Dec 1, 2023, 00:00

  • CO166 Efficacy of Lecanemab in Patients With Early Alzheimer Disease: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • MT39 Development of an Early Economic Model to Assess the Cost-Effectiveness of a Novel Technology for the Treatment and/or Prevention of Cataracts

    Dec 1, 2023, 00:00

  • OP23 Best Practice for Publication of Health Economics and Outcomes Research/Real-World Evidence (RWE) - a Pilot Study on Guidance Needs and Scope for Development

    Dec 1, 2023, 00:00

  • HTA113 How Have Manufacturers Maximised Their Digital Health Technologies’ Chances of Successful Reimbursement in Germany?

    Dec 1, 2023, 00:00

  • EE570 A Swedish Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease

    Dec 1, 2023, 00:00

  • EE279 Model-Projected Long-Term Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) Gene-Edited Therapy in Patients with Transfusion-Dependent Beta-Thalassemia in the United Kingdom

    Dec 1, 2023, 00:00

  • HTA221 Improving the Reimbursement Application Process: A Predictive Model for Identifying Key Subgroup Specification Parameters for Anti-Obesity Medication

    Dec 1, 2023, 00:00

  • EE119 Development of a De Novo Model to Assess the Cost-Effectiveness of a New Treatment Option for Patients With Primary Immunoglobulin a Nephropathy (IgAN)

    Dec 1, 2023, 00:00
  • «
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19 (current)
  • 20
  • »